Signals Blog

Natasha Davie

Natasha Davie is part of the Centre for Accelerating Medical Innovations at Oxford University, where she is pursuing a doctorate in Clinical Laboratory Sciences. She has been involved in regenerative medicine since 2002, when she worked with the London Regenerative Medicine Network on numerous projects analysing cell therapy translation, and gaining expertise in clinical trials, regulation, manufacture and commercialization. She completed her Masters in Biochemical Engineering at University College London in conjunction with the Harvard Stem Cell Institute and Harvard Medical School. Follow Natasha on Twitter @natashadavie

Posts by: Natasha

Value-Based Pricing in regenerative medicine: You get what you pay for

. The UK has previously committed to incorporating some sort of value based pricing into its reimbursement scheme to improve patient access to innovative medicines. With recent backtracking on this decision, as the Jan 2014 deadline for this integration approaches, we examine how such a decision would impact regenerative medicine. The cost of health care […]

To the stars and beyond: Assessing the impact of the $100 Genome

We live in a time of extraordinary medical advances. So far in 2013, we’ve seen the successful transplantation of a bioengineered kidney into rats, an infant reportedly cured of HIV using anti-retroviral drugs that are currently on the market, and discovered a protein that has the potential to ‘reverse aging’ in the heart. These ‘small […]

How many facilities? Centralized vs. decentralized manufacture

When it comes to the cell therapy commercialization crunch there are some fundamental questions that need to be answered. Is your product going to be frozen or fresh? How will the product be administered? What is your dosing strategy? And the one that I’m going to focus on in this blog: Will your manufacturing strategy […]

Fulfilling our pluripotential: iPS cells 6 years on

It has taken just six years since the release of his seminal publication on the genetic reprogramming of human somatic cells for Shinya Yamanaka to be awarded the most prestigious of all accolades: the Nobel Prize. Compare that to his co-recipient, Sir John B. Gurdon, whose critical paper was first published 50 years ago in […]

The Commercialization of Regenerative Medicine: Turning Corners

The health-care landscape is changing: the previous model of the blockbuster pharmaceutical is being challenged by new therapies that have the potential to offer more effective treatments. In this new contribution to Signals Blog, I describe the present landscape for regenerative medicine commercialization. The current health-care system is being pushed to the brink. Driven by […]